

PATIENT INFORMATION					
Name (Last, First, MI)			Biological Sex <input type="checkbox"/> F <input type="checkbox"/> M	Date of Birth (MM/DD/YY)	MRN
Ethnicity: <input type="checkbox"/> African American <input type="checkbox"/> Asian <input type="checkbox"/> Caucasian <input type="checkbox"/> Hispanic <input type="checkbox"/> Portuguese <input type="checkbox"/> Other:					Ashkenazi Jewish <input type="checkbox"/> Yes <input type="checkbox"/> No
Address		City		State	Zip
Preferred Method Of Contact <input type="checkbox"/> Phone <input type="checkbox"/> Text (requires mobile phone number) <input type="checkbox"/> Email		Phone	Email	Preferred Billing <input type="checkbox"/> Insurance <input type="checkbox"/> Cash <input type="checkbox"/> Institutional	
SPECIMEN INFORMATION					
(Both normal sample (e.g. blood or saliva) and tumor tissue required. Please see specimen preparation instruction sheet for detailed specimen requirements.)					
Blood/saliva	Collection Date:	Specimen ID #:		Phlebotomy Services Request:	
Tissue: <input type="checkbox"/> FFPE Block <input type="checkbox"/> Unstained slides (9) Specimen ID #:				<input type="checkbox"/> Phlebotomy draw <input type="checkbox"/> Insurance preverification first	
Collection Date/Date Pulled From Archive: _____ Collection Time: _____ AM/PM		Archived specimen? <input type="checkbox"/> Yes <input type="checkbox"/> No		<input type="checkbox"/> Send kit to patient*	
Fixative/preservative: _____ Body Site: _____		<input type="checkbox"/> Primary <input type="checkbox"/> Metastasis		*As the patient's clinician, I am unaware of any potential for complication or difficulty in drawing blood for the listed patient(s). I understand that the phlebotomist has full authority to refuse to draw any patient if the safety of the phlebotomist and/or patient(s) are in question.	
Primary (if metastasis): _____ Permission to exhaust FFPE block? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Patient discharge date (if within past 30 days): _____					
PATHOLOGY INFORMATION (REQUIRED) <input type="checkbox"/> Please retrieve specimen (To facilitate this process, please complete the specimen forwarding form)					
Pathology report for relevant tumor tissue specimen is REQUIRED for processing. Please include a copy when order is submitted. Tumor specimen will be returned unless otherwise indicated.					
Institution Name		Pathologist		Phone	Fax
Address		City		State	Zip
ORDERING LICENSED PROVIDER/SENDING FACILITY					
Facility Name (Facility Code)		Address		City	State /Country Zip Phone
Ordering Licensed Provider Name (Last, First)(Code)		NPI#	Phone	Fax/Email	
ADDITIONAL RESULTS RECIPIENTS					
Genetic Counselor or Other Medical Provider Name (Last, First) (Code)			Phone/Fax/Email		
Other Medical Provider Name (Last, First) (Code)			Phone/Fax/Email		
CONFIRMATION OF INFORMED CONSENT, PRE-TEST GENETIC COUNSELING, AND MEDICAL NECESSITY FOR GENETIC TESTING					
The undersigned person (or representative thereof) ensures he/she is a licensed medical professional authorized to order genetic testing and confirms that the patient has given appropriate consent. I confirm that testing is medically necessary and that test results may impact medical management for the patient. I agree to allow Ambry Genetics to facilitate the provision of pre-test genetic counseling services by a third-party service, as required by the patient's insurance provider. Furthermore, all information on this TRF is true to the best of my knowledge. My signature applies to the attached letter of medical necessity.					
Signature Required for Processing Medical Professional Signature:				Date:	
INSURANCE BILLING (Include copy of both sides of insurance card)			INSTITUTIONAL BILLING		
Patient Relation to Policy Holder? <input type="checkbox"/> Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child		Name and DOB of Policy Holder (if not self)		Facility Name <input type="checkbox"/> Send invoice to facility address above	
Insurance Company		Policy #	HMO Auth #	Address	
Out Of Pocket (OOP): We will start testing immediately, unless you check the box below. We will attempt to contact the patient if the estimated out-of-pocket costs are > USD \$100. <input type="checkbox"/> Do not start testing until my patient approves payment terms regarding estimated out-of-pocket costs By checking this box, I understand that there will be a delay in starting this test until Ambry is able to reach the patient to communicate OOP costs.			Contact Name		
Special Billing Notes:			Phone Number		E-mail/Fax
			<input type="checkbox"/> PATIENT PAYMENT		<input type="checkbox"/> Check (Payable to Ambry Genetics) <input type="checkbox"/> Credit Card (Call 949-900-5795)
Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to Ambry Genetics Corporation (Ambry), authorize Ambry to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and responsible for sending Ambry money received from my health insurance company. For patient payment by credit card: I hereby authorize Ambry Genetics Corporation to bill my credit card as indicated above. In order to expedite consideration for eligibility for Ambry's Patient Assistance Program , please provide the total annual gross household income: \$ _____ and the number of family members in the household supported by the listed income: _____. I authorize Ambry Genetics Corporation to verify the above information for the sole purpose of assessing financial need, including the right to seek supporting documentation.					
FOR NY RESIDENTS: <input type="checkbox"/> I am a New York resident and I give Ambry Genetics permission to store my sample for longer than 60 days. NOTE: If left blank, consent is interpreted as "NO".					
Signature Required For Insurance/Self-Pay Patients and NY Sample Storage Consent:				Date:	

Tumor Test Requisition Form - Page 2 of 2

PLEASE SUBMIT THE FOLLOWING WITH THE TRF:

1. Clinic Notes 2. Pedigree 3. Insurance Card

PATIENT CLINICAL HISTORY (Please indicate if diagnosis is active)											
<input type="checkbox"/> No personal history of cancer				<input type="checkbox"/> History of allogenic bone marrow or peripheral stem cell transplant*				ICD-10 code(s):			
Cancer/Tumor	Active	Age at Dx	Pathology and Other Info								
Breast	<input type="checkbox"/>		Type:		ER <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk	PR <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk	HER2/neu <input type="checkbox"/> (+) <input type="checkbox"/> (-) <input type="checkbox"/> unk				
Colorectal	<input type="checkbox"/>		Location:								
Uterine	<input type="checkbox"/>										
Ovarian	<input type="checkbox"/>		<input type="checkbox"/> Fallopian tube <input type="checkbox"/> Primary peritoneal								
Prostate	<input type="checkbox"/>		Gleason Score:				Metastatic: <input type="checkbox"/> Y <input type="checkbox"/> N				
Other Cancer	<input type="checkbox"/>		Type:								
Other clinical history:											
<i>*Blood or saliva from patients with active/recent hematological disease will undergo additional review and may not be accepted in some cases. For these, cultured fibroblasts or fresh/fresh frozen normal tissue are preferred. See ambrygen.com for details.</i>											
PATIENT GENETIC TESTING HISTORY						Lynch syndrome tests only: This section must be completed for Medicare beneficiaries					
<input type="checkbox"/> No previous molecular and/or genetic testing											
Genetic testing Test(s) performed: _____					Microsatellite instability analysis:						
Result(s): _____					<input type="checkbox"/> Stable (MSS) <input type="checkbox"/> Unstable/high (MSI-H) <input type="checkbox"/> Unstable/low (MSI-L)						
Please include copies of any previous genetic test results.					IHC, if multiple primaries, tumor used: _____						
					<input type="checkbox"/> Proteins present: _____ <input type="checkbox"/> Proteins absent: _____						
					<input type="checkbox"/> Tissue is unavailable or insufficient for IHC/MSI testing						
FAMILY HISTORY†											
<i>†Completing this section is not mandatory for ordering if a pedigree and/or clinical note with family history is supplied, but is recommended and helps with results interpretation and claims filing.</i>											
<input type="checkbox"/> None (maternal) <input type="checkbox"/> None (paternal) <input type="checkbox"/> Maternal history unknown <input type="checkbox"/> Paternal history unknown											
Relation to patient	Maternal	Paternal	Cancer/Polyp Type	Dx age	Relation to patient	Maternal	Paternal	Cancer/Polyp Type	Dx age		
	<input type="checkbox"/>	<input type="checkbox"/>				<input type="checkbox"/>	<input type="checkbox"/>				
	<input type="checkbox"/>	<input type="checkbox"/>				<input type="checkbox"/>	<input type="checkbox"/>				
	<input type="checkbox"/>	<input type="checkbox"/>				<input type="checkbox"/>	<input type="checkbox"/>				
TESTS REQUESTED											
Check to order	Test Name	Test Code	Description								
<i>Both normal sample (e.g. blood or saliva) and tumor tissue are required. Please see specimen preparation instruction sheet for more detailed specimen requirements.</i>											
<input type="checkbox"/>	Lynch syndrome paired testing*	8982	Paired tumor and germline testing of <i>MLH1, MSH2, MSH6, PMS2, + EPCAM del/dup</i>								
<input type="checkbox"/>	TumorNext- Lynch *	8980	Paired tumor and germline testing of <i>MLH1, MSH2, MSH6, PMS2, and EPCAM</i> ; microsatellite instability (MSI) and <i>MLH1</i> promoter hypermethylation analysis								
<input type="checkbox"/>	TumorNext-Lynch plus ColoNext®*	8981	TumorNext-Lynch (described above) plus germline analysis of 12 additional genes								
<input type="checkbox"/>	TumorNext-Lynch plus OvaNext®*	8983	TumorNext-Lynch (described above) plus germline analysis of 20 additional genes								
<input type="checkbox"/>	TumorNext-Lynch plus CancerNext®*	8984	TumorNext-Lynch (described above) plus germline analysis of 29 additional genes								
<input type="checkbox"/>	Add on <i>BRAF (V600E), KRAS, and NRAS</i> targeted analysis (This can only be applied to test options above.)										
<input type="checkbox"/>	Microsatellite instability (MSI) analysis*, **	8702									
<input type="checkbox"/>	<i>MLH1</i> promoter hypermethylation analysis*	7978									
<i>*Lynch syndrome tumors will be accepted. Visit ambrygen.com for more details.</i>											
<input type="checkbox"/>	TumorNext-BRCA**	9810	Paired tumor and germline analysis of <i>BRCA1</i> and <i>BRCA2</i>								
<input type="checkbox"/>	TumorNext-HRD**	9811	Paired tumor and germline analysis of <i>BRCA1</i> and <i>BRCA2</i> plus 9 additional genes								
<input type="checkbox"/>	TumorNext-HRD plus OvaNext**	9812	TumorNext-HRD (described above) plus germline analysis of 14 additional genes								
<input type="checkbox"/>	TumorNext-HRD plus CancerNext**	9813	TumorNext-HRD (described above) plus germline analysis of 23 additional genes								
<i>**Ovarian tumors (including Fallopian tube and primary peritoneal) will be accepted. For other cancer types, please discuss with your Ambry Account Manager.</i>											
Will patient management be changed depending on the test results? <input type="checkbox"/> Yes <input type="checkbox"/> No					For assistance regarding requested tumor samples, please call 949.900.5783.						
Notes:											

 For complete gene lists or additional test information, please visit ambrygen.com